来那替尼 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "来那替尼" in Chinese language version.

refsWebsite

Global rank Chinese rank

12web.archive.org

1^st place

11nih.gov

4^th place

5^th place

5worldcat.org

5^th place

12^th place

4doi.org

2^nd place

23^rd place

4fda.gov

447^th place

581^st place

1europa.eu

68^th place

209^th place

1genengnews.com

low place

doi.org

Baselga, José; Coleman, Robert E.; Cortés, Javier; Janni, Wolfgang. Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology. 2017-11, 119 [2022-06-12]. ISSN 1879-0461. PMC 5662944 . PMID 29042085. doi:10.1016/j.critrevonc.2017.10.001. （原始内容存档于2022-06-16）.
Minami, Y.; Shimamura, T.; Shah, K.; LaFramboise, T.; Glatt, K. A.; Liniker, E.; Borgman, C. L.; Haringsma, H. J.; Feng, W.; Weir, B. A.; Lowell, A. M. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007-07-26, 26 (34) [2022-06-12]. ISSN 0950-9232. PMID 17311002. doi:10.1038/sj.onc.1210292. （原始内容存档于2022-06-19）.
Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America. 2008-02-12, 105 (6) [2022-06-12]. ISSN 1091-6490. PMC 2538882 . PMID 18227510. doi:10.1073/pnas.0709662105. （原始内容存档于2022-06-15）.
Santamaria, Sara; Gagliani, Maria Cristina; Bellese, Grazia; Marconi, Silvia; Lechiara, Anastasia; Dameri, Martina; Aiello, Cinzia; Tagliatti, Erica; Castagnola, Patrizio; Cortese, Katia. Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 2021-07, 69 (7) [2022-06-12]. ISSN 1551-5044. PMC 8246527 . PMID 34126793. doi:10.1369/00221554211026297. （原始内容存档于2021-11-28）.

europa.eu

ema.europa.eu

Nerlynx. European Medicines Agency. [2022-06-12]. （原始内容存档于2020-11-20）（英语）.

fda.gov

Commissioner, Office of the. FDA approves new treatment to reduce the risk of breast cancer returning. FDA. 2020-03-24 [2022-06-12]. （原始内容存档于2020-10-27）（英语）.
Research, Center for Drug Evaluation and. FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer. FDA. 2018-11-03 [2022-06-12]. （原始内容存档于2020-10-29）（英语）.
Research, Center for Drug Evaluation and. Drug Trials Snapshot: NERLYNX. FDA. 2019-02-09 [2022-06-12]. （原始内容存档于2020-12-02）（英语）.

accessdata.fda.gov

Nerlynx (neratinib maleate) Tablets. Drug Approvals and Databases. [2022-06-12]. （原始内容存档于2020-11-14）.

genengnews.com

Puma Acquires Global Rights to Pfizer’s Phase III Breast Cancer Drug Neratinib. GEN. 2011-10-06 [2022-06-12]. （原始内容存档于2018-09-20）.

nih.gov

ncbi.nlm.nih.gov

Baselga, José; Coleman, Robert E.; Cortés, Javier; Janni, Wolfgang. Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology. 2017-11, 119 [2022-06-12]. ISSN 1879-0461. PMC 5662944 . PMID 29042085. doi:10.1016/j.critrevonc.2017.10.001. （原始内容存档于2022-06-16）.
Minami, Y.; Shimamura, T.; Shah, K.; LaFramboise, T.; Glatt, K. A.; Liniker, E.; Borgman, C. L.; Haringsma, H. J.; Feng, W.; Weir, B. A.; Lowell, A. M. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007-07-26, 26 (34) [2022-06-12]. ISSN 0950-9232. PMID 17311002. doi:10.1038/sj.onc.1210292. （原始内容存档于2022-06-19）.
Vissavajjhala, P.; Ross, A. H. Purification and characterization of the recombinant extracellular domain of human nerve growth factor receptor expressed in a baculovirus system. The Journal of Biological Chemistry. 1990-03-15, 265 (8) [2022-06-12]. ISSN 0021-9258. PMID 2155239. （原始内容存档于2022-06-12）.
Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America. 2008-02-12, 105 (6) [2022-06-12]. ISSN 1091-6490. PMC 2538882 . PMID 18227510. doi:10.1073/pnas.0709662105. （原始内容存档于2022-06-15）.
Santamaria, Sara; Gagliani, Maria Cristina; Bellese, Grazia; Marconi, Silvia; Lechiara, Anastasia; Dameri, Martina; Aiello, Cinzia; Tagliatti, Erica; Castagnola, Patrizio; Cortese, Katia. Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 2021-07, 69 (7) [2022-06-12]. ISSN 1551-5044. PMC 8246527 . PMID 34126793. doi:10.1369/00221554211026297. （原始内容存档于2021-11-28）.

pubmed.ncbi.nlm.nih.gov

Baselga, José; Coleman, Robert E.; Cortés, Javier; Janni, Wolfgang. Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology. 2017-11, 119 [2022-06-12]. ISSN 1879-0461. PMC 5662944 . PMID 29042085. doi:10.1016/j.critrevonc.2017.10.001. （原始内容存档于2022-06-16）.
Minami, Y.; Shimamura, T.; Shah, K.; LaFramboise, T.; Glatt, K. A.; Liniker, E.; Borgman, C. L.; Haringsma, H. J.; Feng, W.; Weir, B. A.; Lowell, A. M. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007-07-26, 26 (34) [2022-06-12]. ISSN 0950-9232. PMID 17311002. doi:10.1038/sj.onc.1210292. （原始内容存档于2022-06-19）.
Vissavajjhala, P.; Ross, A. H. Purification and characterization of the recombinant extracellular domain of human nerve growth factor receptor expressed in a baculovirus system. The Journal of Biological Chemistry. 1990-03-15, 265 (8) [2022-06-12]. ISSN 0021-9258. PMID 2155239. （原始内容存档于2022-06-12）.
Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America. 2008-02-12, 105 (6) [2022-06-12]. ISSN 1091-6490. PMC 2538882 . PMID 18227510. doi:10.1073/pnas.0709662105. （原始内容存档于2022-06-15）.
Santamaria, Sara; Gagliani, Maria Cristina; Bellese, Grazia; Marconi, Silvia; Lechiara, Anastasia; Dameri, Martina; Aiello, Cinzia; Tagliatti, Erica; Castagnola, Patrizio; Cortese, Katia. Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 2021-07, 69 (7) [2022-06-12]. ISSN 1551-5044. PMC 8246527 . PMID 34126793. doi:10.1369/00221554211026297. （原始内容存档于2021-11-28）.

dailymed.nlm.nih.gov

NERLYNX- neratinib tablet. DailyMed. [2022-06-12]. （原始内容存档于2020-11-18）.

web.archive.org

NERLYNX- neratinib tablet. DailyMed. [2022-06-12]. （原始内容存档于2020-11-18）.
Nerlynx. European Medicines Agency. [2022-06-12]. （原始内容存档于2020-11-20）（英语）.
Baselga, José; Coleman, Robert E.; Cortés, Javier; Janni, Wolfgang. Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology. 2017-11, 119 [2022-06-12]. ISSN 1879-0461. PMC 5662944 . PMID 29042085. doi:10.1016/j.critrevonc.2017.10.001. （原始内容存档于2022-06-16）.
Minami, Y.; Shimamura, T.; Shah, K.; LaFramboise, T.; Glatt, K. A.; Liniker, E.; Borgman, C. L.; Haringsma, H. J.; Feng, W.; Weir, B. A.; Lowell, A. M. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007-07-26, 26 (34) [2022-06-12]. ISSN 0950-9232. PMID 17311002. doi:10.1038/sj.onc.1210292. （原始内容存档于2022-06-19）.
Vissavajjhala, P.; Ross, A. H. Purification and characterization of the recombinant extracellular domain of human nerve growth factor receptor expressed in a baculovirus system. The Journal of Biological Chemistry. 1990-03-15, 265 (8) [2022-06-12]. ISSN 0021-9258. PMID 2155239. （原始内容存档于2022-06-12）.
Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America. 2008-02-12, 105 (6) [2022-06-12]. ISSN 1091-6490. PMC 2538882 . PMID 18227510. doi:10.1073/pnas.0709662105. （原始内容存档于2022-06-15）.
Santamaria, Sara; Gagliani, Maria Cristina; Bellese, Grazia; Marconi, Silvia; Lechiara, Anastasia; Dameri, Martina; Aiello, Cinzia; Tagliatti, Erica; Castagnola, Patrizio; Cortese, Katia. Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 2021-07, 69 (7) [2022-06-12]. ISSN 1551-5044. PMC 8246527 . PMID 34126793. doi:10.1369/00221554211026297. （原始内容存档于2021-11-28）.
Puma Acquires Global Rights to Pfizer’s Phase III Breast Cancer Drug Neratinib. GEN. 2011-10-06 [2022-06-12]. （原始内容存档于2018-09-20）.
Nerlynx (neratinib maleate) Tablets. Drug Approvals and Databases. [2022-06-12]. （原始内容存档于2020-11-14）.
Commissioner, Office of the. FDA approves new treatment to reduce the risk of breast cancer returning. FDA. 2020-03-24 [2022-06-12]. （原始内容存档于2020-10-27）（英语）.
Research, Center for Drug Evaluation and. FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer. FDA. 2018-11-03 [2022-06-12]. （原始内容存档于2020-10-29）（英语）.
Research, Center for Drug Evaluation and. Drug Trials Snapshot: NERLYNX. FDA. 2019-02-09 [2022-06-12]. （原始内容存档于2020-12-02）（英语）.

worldcat.org

Baselga, José; Coleman, Robert E.; Cortés, Javier; Janni, Wolfgang. Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology. 2017-11, 119 [2022-06-12]. ISSN 1879-0461. PMC 5662944 . PMID 29042085. doi:10.1016/j.critrevonc.2017.10.001. （原始内容存档于2022-06-16）.
Minami, Y.; Shimamura, T.; Shah, K.; LaFramboise, T.; Glatt, K. A.; Liniker, E.; Borgman, C. L.; Haringsma, H. J.; Feng, W.; Weir, B. A.; Lowell, A. M. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007-07-26, 26 (34) [2022-06-12]. ISSN 0950-9232. PMID 17311002. doi:10.1038/sj.onc.1210292. （原始内容存档于2022-06-19）.
Vissavajjhala, P.; Ross, A. H. Purification and characterization of the recombinant extracellular domain of human nerve growth factor receptor expressed in a baculovirus system. The Journal of Biological Chemistry. 1990-03-15, 265 (8) [2022-06-12]. ISSN 0021-9258. PMID 2155239. （原始内容存档于2022-06-12）.
Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America. 2008-02-12, 105 (6) [2022-06-12]. ISSN 1091-6490. PMC 2538882 . PMID 18227510. doi:10.1073/pnas.0709662105. （原始内容存档于2022-06-15）.
Santamaria, Sara; Gagliani, Maria Cristina; Bellese, Grazia; Marconi, Silvia; Lechiara, Anastasia; Dameri, Martina; Aiello, Cinzia; Tagliatti, Erica; Castagnola, Patrizio; Cortese, Katia. Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 2021-07, 69 (7) [2022-06-12]. ISSN 1551-5044. PMC 8246527 . PMID 34126793. doi:10.1369/00221554211026297. （原始内容存档于2021-11-28）.